Drugs / QIV-HD
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03233217 | Sep → Nov 2017 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03282240 | Sep → Nov 2017 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05624606 Comparator | Nov 2022 → Mar 2024 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-10-07 | Sanofi | Results Sanofi: Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations sanofi.com ↗
This is the first study to provide supportive evidence for vaccinating against influenza at the same time as a COVID-19 mRNA booster in seniors. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-10-07 | Sanofi | Sanofi: Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations sanofi.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QIV-HD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03282240 ↗ |
| Known as | IIV4-HD | “quadrivalent high-dose split-virion inactivated influenza vaccine (IIV4-HD)” PMID 31431411 ↗ Aug 2019 |
| Modality | Vaccine | “high-dose Quadrivalent influenza vaccine (QIV-HD)” NCT03233217 ↗ |
| Route | Intramuscular | “QIV-HD by IM route” NCT03233217 ↗ |